Biotech Values

[DewDiligence]

>AGN – I know a number of female glaucoma patients who have switched from Lumigan to alternatives because of darkening of the eyelids.<

The method of application has prevented this from happening with Latisse—so far. However, for this kind of product, clinical trials might not predict what will happen in real-world use, where users are apt to be somewhat less diligent and precise. If the staining problem does turn up, the $500M+ sales forecast clearly goes out the window.